Myomo, Inc.

Myomo, Inc. is a medical robotics company specializing in the development and marketing of myoelectric orthotics for individuals with neuromuscular disorders. Headquartered in Burlington, Massachusetts, the company's mission is to improve the lives of people by providing effective, safe, and reliable medical products and services. Myomo aims to restore mobility and independence for those suffering from paralyzed arms due to conditions such as stroke, spinal cord injury, or other neurological impairments.

The company's primary product line is MyoPro®, a series of lightweight, non-invasive, powered arm braces (orthoses). These FDA-registered Class II medical devices utilize a patient's own electromyography (EMG) signals, detected through non-invasive sensors, to enable and restore function in weakened or paralyzed arms and hands. MyoPro devices are designed to assist patients in performing activities of daily living. Myomo also offers support services such as MyoCare, a post-delivery program, and digital tools like MyoGames and the MyoPro 2x Video Library. The company distributes its products through orthotics and prosthetics providers, the Veterans Health Administration, and other distributors, with a growing international presence in markets like Germany.

Recent developments for Myomo include strong financial performance in Q1 2026, with revenues reaching $10.1 million and exceeding forecasts, though the stock has experienced volatility. A significant milestone was achieved on April 1, 2024, when the Centers for Medicare & Medicaid Services (CMS) began reimbursing the MyoPro under Medicare Part B, substantially expanding patient access. The company has also expanded its reach through partnerships, such as making MyoPro available at Ottobock Care Clinics in the U.S., and continues to focus on international growth and product enhancements, including the introduction of a mobile app. Paul R. Gudonis serves as the President, CEO, and Chairman.